ATE142497T1 - Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen - Google Patents

Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen

Info

Publication number
ATE142497T1
ATE142497T1 AT90111787T AT90111787T ATE142497T1 AT E142497 T1 ATE142497 T1 AT E142497T1 AT 90111787 T AT90111787 T AT 90111787T AT 90111787 T AT90111787 T AT 90111787T AT E142497 T1 ATE142497 T1 AT E142497T1
Authority
AT
Austria
Prior art keywords
physical
treatment
ranolazine
piperazines
chemical damage
Prior art date
Application number
AT90111787T
Other languages
English (en)
Inventor
Robert J Dow
Pierre Ferrandon
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of ATE142497T1 publication Critical patent/ATE142497T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT90111787T 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen ATE142497T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
ATE142497T1 true ATE142497T1 (de) 1996-09-15

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
AT90111787T ATE142497T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
AT95119463T ATE218344T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von schockzuständen
AT95119452T ATE223218T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT95119463T ATE218344T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von schockzuständen
AT95119452T ATE223218T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur

Country Status (13)

Country Link
US (2) US5506229A (de)
EP (3) EP0407780B1 (de)
JP (1) JP3232085B2 (de)
AT (3) ATE142497T1 (de)
AU (1) AU633589B2 (de)
CA (1) CA2019580C (de)
DE (3) DE69028457T2 (de)
DK (3) DK0714660T3 (de)
ES (3) ES2177601T3 (de)
GR (1) GR3020976T3 (de)
IE (1) IE80710B1 (de)
NZ (2) NZ247044A (de)
ZA (1) ZA904842B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
AU758370B2 (en) * 1997-08-08 2003-03-20 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001062711A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
AU2001238590A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
NZ520782A (en) * 2000-02-22 2004-03-26 Cv Therapeutics Inc Substituted piperazine compounds that are partial fatty acid oxidation inhibitors
AU2001285245A1 (en) * 2000-08-25 2002-03-13 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
ATE365737T1 (de) 2002-12-05 2007-07-15 Cv Therapeutics Inc Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
NZ541069A (en) 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
WO2004069818A1 (en) 2003-01-17 2004-08-19 Cv Therapeutics Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
CA2530376A1 (en) 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
MX2007005367A (es) * 2004-11-09 2007-06-18 Cv Therapeutics Inc Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (de) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Verwendung von ranolazin zur behandlung koronarer mikrovaskulärer erkrankungen
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
EP2515880B1 (de) 2009-05-28 2019-11-27 Lupin Limited Neuartige pharmazeutische zusammensetzungen mit ranolazin
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
EP2453893A4 (de) 2009-07-09 2012-06-20 Ozteo Pty Ltd Behandlung nicht neuronaler und nicht myokardialer zell-, gewebe- und organschäden und der damit verbundenen schmerzen durch dauerhafte natriumkanalblocker
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
JP2024537585A (ja) * 2021-09-27 2024-10-16 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッド 心筋虚血の治療のための医薬組成物及びその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
EP0719558A1 (de) 1996-07-03
DE69034000T2 (de) 2003-06-05
EP0719558B1 (de) 2002-06-05
DE69028457D1 (de) 1996-10-17
DK0407780T3 (da) 1996-09-30
IE902250A1 (en) 1991-01-16
ES2091211T3 (es) 1996-11-01
ATE218344T1 (de) 2002-06-15
ATE223218T1 (de) 2002-09-15
ES2182863T3 (es) 2003-03-16
DE69034000D1 (de) 2002-10-10
US5506229A (en) 1996-04-09
DE69028457T2 (de) 1997-02-20
ZA904842B (en) 1992-02-26
IE902250L (en) 1990-12-23
DE69033967D1 (de) 2002-07-11
CA2019580A1 (en) 1990-12-23
NZ234184A (en) 1997-01-29
AU633589B2 (en) 1993-02-04
JP3232085B2 (ja) 2001-11-26
AU5761890A (en) 1991-01-03
ES2177601T3 (es) 2002-12-16
EP0407780A2 (de) 1991-01-16
EP0407780B1 (de) 1996-09-11
CA2019580C (en) 2007-03-27
EP0714660B1 (de) 2002-09-04
EP0714660A1 (de) 1996-06-05
NZ247044A (en) 1997-04-24
DK0719558T3 (da) 2002-10-07
DK0714660T3 (da) 2002-10-07
DE69033967T2 (de) 2002-12-19
GR3020976T3 (en) 1996-12-31
EP0407780A3 (en) 1992-01-02
JPH0348672A (ja) 1991-03-01
IE80710B1 (en) 1998-12-16
US5906988A (en) 1999-05-25

Similar Documents

Publication Publication Date Title
DE69033967D1 (de) Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
DE58902313D1 (de) Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE384703T1 (de) Piperazinyl-substituierte phenylpyrimidinderivative zur behandlung oder vorbeugung von zns erkrankungen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69018043D1 (de) Behandlung von Geflügel.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DK388488D0 (da) Benzolthiophenderivater og fremgangsmaade til fremstilling deraf
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
DE59003534D1 (de) Verfahren zur Herstellung von Triethylendiamin und Piperazin.
DE59005066D1 (de) Verfahren und Vorrichtung zum Keimfreimachen, Desinfizieren und/oder Trocknen.
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
DE3486005D1 (de) Anwendung von carbamate oder thiocarbamat-derivaten zur behandlung von fungus-infektionen.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE303158T1 (de) Verwendung von beta-interferon zur behandlung der restenose
DE69019674D1 (de) Phenoxypropylaminderivate oder Salze davon und sie enthaltende Antiulcuswirkstoffe.
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
DE3576498D1 (de) 2-sulfamoyl-1h-indole-derivate zur behandlung von hohem intraocularem druck.
ATA532579A (de) Einrichtung zur behandlung von waesserigen suspensionen
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
ATE17716T1 (de) Verbindungen und methode zur behandlung oder prophylaxis von herzstoerungen.
ATA256280A (de) Sterilisation oder entseuchung von apparaturen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time